Sulindac disorder

Clinical use Sulindac (Brogden, 1978a) is a nonsteroidal anti-inflammatory drug used in the treatment of mild to moderate pain including musculoskeletal and joint disorders such as rheumatoid arthritis, osteoarthritis and gout. 

The development of aspirin was a significant landmark in the history of medicine because it stimulated the development of a family of medicines, collectively known as the nonsteroidal antiinflammatory drugs (NSAIDs). NSAIDs such as ibuprofen, naproxen, and sulindac are valuable drugs used for the alleviation of pain, inflammation, and fever, and they are commonly prescribed for the treatment of rheumatoid disorders such as arthritis. The world market for NSAIDs now exceeds 6 billion (Vainio and Morgan, 1997). 

Additionally, patients with familial adenomatous polyposis, an autosomal-dominant disease characterized by numerous small intestinal and colonic polyps with a nearly universal progression to colon cancer, have a favorable response to NSAIDs. Administration of NSAID (usually sulindac) to patients with this disorder reduces the number and size of polyps (DuBois et al., 1996). Recent biochemical evidence indicates that colon polyps and colon cancer are frequendy associated with induction of Cox-2 in the lesion as assessed by expression of Cox-2 mRNA and protein. Such induction appears to correlate with growth of the lesion, and inhibition of Cox-2 correlates with apoptosis of the involved cells (Gupta and DuBois, 1998). 

Indomethacin was the product of a laboratory search for drugs with antiinflammatory properties. It was introduced in 1963 for the treatment of rheumatoid arthritis and related disorders. It is a nonselective COX inhibitor. Although indomethacin still is used clinically and is effective, toxicity and the availability of safer alternatives have limited its use. Sulindac was developed in an attempt to find a less toxic, but effective, congener of indomethacin and also is a nonselective COX inhibitor. 

---

See also in sourсe #XX -- [ ]

---